Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Article

Oncology Clinics Frustrated With Manufacturer Engagement Tactics

June 11, 2024
Authors
Topics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Frustrated man surrounded by technology, papers, people.

The oncology toolbox is growing rapidly, with novel treatments or expanded uses being approved almost monthly. Understandably, manufacturers seek to ensure that oncologists are informed of the details for new and existing treatments, and community oncologists generally find product updates to be highly useful. However, an increasingly crowded market is forcing companies to compete for the limited time physicians and practices can allocate for these meetings.

Our 2024 Community Oncology Annual Trend survey examined practices’ points of view toward manufacturers’ digital engagement to identify frustrations arising from current approaches (Figure). HMP Market Access Insight’s (MAI’s) research suggests that manufacturers who engage with providers on their terms are more likely to avoid these causes of frustration.

Figure showing data described in article.

Figure. Prevalence and Causes of Community Oncology Practices’ Frustrations. (A) Perceived frustrations and inefficiencies with digital manufacturer communications (N = 124 practices). (B) Top three oncology clinic frustrations with manufacturer engagement tactics (N = 113 practices).
Source: HMP Market Access Insights 2024 Community Oncology Annual Trend report. 

Key findings include:

  • Overall frustration: 91% of surveyed practices have declared some type of frustration with current manufacturer engagement tactics.
  • Inefficient communication: 55% of practices believe they are receiving excessive email communication, and 52% have experienced uncoordinated meeting requests from different representatives at the same manufacturer. This demonstrates a need for more streamlined and coordinated communication strategies.
  • “Meet clinics where they are”: 54% of practices report that they receive communication at inconvenient times. Manufacturers may increase communication effectiveness by aligning their engagements with practices’ daily schedule.

We look forward to sharing additional insights later this month when we release our full 2024 Community Oncology Annual Trend report!

Meanwhile, be sure to check out some of our newly available reports and keep an eye out for our other upcoming offerings:

If your organization is interested in learning more about our offerings, please contact Sara Stewart.

The Latest

Key takeaways from CPC+CBEx 2024
Article
Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Daniel Buchenberger
Figure 1: Community Oncology Actions to Address Any Potential Impact of the IRA   Source: HMP Market Access Insights 2024 Community, and Payer Oncology Trend Report.
Article
Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Emma Bijesse
Prior Authorization Requirements Continue to Impact Providers

Welcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.

Emma Bijesse